METASTATIC PROSTATE CANCER
Clinical trials for METASTATIC PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis early-stage study tests an experimental drug called AZD8359 in 42 adults with metastatic prostate cancer that has worsened despite prior treatments. The drug is designed to help the immune system attack cancer cells. The study aims to find the safest and most effective dose …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for advanced prostate cancer: GDC-1261 trial begins
Disease control Not yet recruitingThis study tests a new drug, GDC-1261, in 260 people with advanced or metastatic prostate cancer that has worsened despite prior treatment. The goal is to check the drug's safety, find the best dose, and see if it can slow the cancer. Participants must continue standard hormone t…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Diabetes drug shows promise against advanced prostate cancer in new trial
Disease control Not yet recruitingThis phase 2 trial tests whether adding dapagliflozin, a common diabetes medication, to standard hormone therapy can better control metastatic castrate-resistant prostate cancer. About 60 adults with advanced prostate cancer that has stopped responding to hormone therapy will be …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE2 • Sponsor: Yung NA • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Could surgery after meds tame tough prostate cancer?
Disease control Not yet recruitingThis study tests whether men with advanced prostate cancer that has spread to other parts of the body can benefit from having their prostate removed after initial drug therapy. Participants first receive 6 months of hormone-blocking drugs. Those whose scans show the cancer has qu…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
Low-Dose naltrexone tested as fatigue fighter for prostate cancer patients
Symptom relief Not yet recruitingThis study tests whether a small daily dose of naltrexone (3 mg) can ease severe tiredness in men with prostate cancer who are on hormone therapy (ADT). Researchers will measure fatigue, inflammation, and quality of life in 60 participants. The goal is to find a safe, simple way …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Arkansas • Aim: Symptom relief
Last updated May 15, 2026 11:53 UTC
-
Brazilian study maps genetic secrets of advanced prostate cancer
Knowledge-focused Not yet recruitingThis study aims to understand genetic changes in metastatic prostate cancer and how they affect patient outcomes. It will involve 100 adults in Brazil who are receiving standard palliative therapy. Researchers will analyze tumor and blood samples to identify key mutations, but no…
Matched conditions: METASTATIC PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 15, 2026 11:53 UTC
-
AI-Powered registry to track Real-World use of prostate cancer drug
Knowledge-focused Not yet recruitingThis study will collect information from about 753 patients with metastatic prostate cancer who receive a drug called lutetium-177 vipivotide tetraxetan. The goal is to understand how the drug is used in everyday medical practice and what outcomes patients experience. No new trea…
Matched conditions: METASTATIC PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC